Total Payments
$45,446
2024 Payments
$8,442
Companies
9
Transactions
36
Medicare Patients
794
Medicare Billing
$273,423
Payment Breakdown by Category
Research$23,842 (52.5%)
Consulting$19,408 (42.7%)
Other$1,800 (4.0%)
Food & Beverage$397.06 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23,842 | 19 | 52.5% |
| Consulting Fee | $19,408 | 10 | 42.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,800 | 1 | 4.0% |
| Food and Beverage | $397.06 | 6 | 0.9% |
Payments by Type
Research
$23,842
19 transactions
General
$21,605
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32,325 | 13 | $0 (2024) |
| Novartis Pharma AG | $9,347 | 14 | $0 (2024) |
| SANOFI US SERVICES INC. | $1,800 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,028 | 1 | $0 (2024) |
| ABBVIE INC. | $550.00 | 1 | $0 (2023) |
| Incyte Corporation | $160.58 | 2 | $0 (2017) |
| Astellas Pharma US Inc | $146.79 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $64.94 | 2 | $0 (2019) |
| GlaxoSmithKline, LLC. | $24.75 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,442 | 16 | Novartis Pharma AG ($3,707) |
| 2023 | $9,876 | 3 | Novartis Pharmaceuticals Corporation ($7,916) |
| 2022 | $10,173 | 5 | Novartis Pharmaceuticals Corporation ($6,883) |
| 2021 | $13,440 | 6 | Novartis Pharmaceuticals Corporation ($12,500) |
| 2020 | $1,880 | 1 | Novartis Pharmaceuticals Corporation ($1,880) |
| 2019 | $1,475 | 3 | Novartis Pharmaceuticals Corporation ($1,410) |
| 2017 | $160.58 | 2 | Incyte Corporation ($160.58) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/15/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $187.63 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 12/08/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $453.74 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 10/11/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $453.74 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 09/14/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $146.79 | General |
| Category: Oncology | ||||||
| 09/04/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | — | Cash or cash equivalent | $1,229.09 | Research |
| Study: CABL001AUS04 • Category: Oncology | ||||||
| 08/01/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $187.63 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 06/20/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $431.05 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 06/01/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | — | Cash or cash equivalent | $506.79 | Research |
| Study: Research Publication/ Writing Support • Category: Oncology | ||||||
| 05/31/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $453.74 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 04/24/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $187.63 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 04/15/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $985.68 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 03/22/2024 | SANOFI US SERVICES INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| 03/01/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $178.25 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 02/26/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,027.50 | General |
| 02/06/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $187.63 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 08/01/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | — | Cash or cash equivalent | $7,916.00 | Research |
| Study: CABL001AUS04 • Category: Oncology | ||||||
| 04/25/2023 | Novartis Pharma AG | SCEMBLIX (Drug) | — | Cash or cash equivalent | $1,410.00 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 01/04/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2022 | Novartis Pharma AG | SCEMBLIX (Drug) | — | Cash or cash equivalent | $1,410.00 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 09/16/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | SCEMBLIX (Drug) | — | In-kind items and services | $2,683.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: ONCOLOGY | ||||||
| 08/23/2022 | Novartis Pharma AG | SCEMBLIX (Drug) | — | Cash or cash equivalent | $1,880.00 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 05/13/2022 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 05/01/2022 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: ONCOLOGY | ||||||
| 09/14/2021 | Novartis Pharma AG | SCEMBLIX (Drug) | — | Cash or cash equivalent | $940.00 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CABL001J12301 | Novartis Pharma AG | $9,347 | 14 |
| CABL001AUS04 | Novartis Pharmaceuticals Corporation | $9,145 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,683 | 1 |
| AN OPEN LABEL, MULTI-CENTER PHASE IIIB STUDY OF ASCIMINIB (ABL001) MONOTHERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA ON CHRONIC PHASE (CML-CP) PREVIOUSLY TREATED WITH AT LEAST 2 PRIOR TKIS (TYROSINE KINASE INHIBITORS) | Novartis Pharmaceuticals Corporation | $2,160 | 1 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $506.79 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 251 | 1,053 | $373,831 | $102,748 |
| 2022 | 5 | 185 | 576 | $213,381 | $51,693 |
| 2021 | 5 | 212 | 817 | $277,929 | $73,088 |
| 2020 | 4 | 146 | 568 | $184,719 | $45,893 |
Total Patients
794
Total Services
3,014
Medicare Billing
$273,423
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 98 | 687 | $196,551 | $65,933 | 33.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 97 | 295 | $157,660 | $32,096 | 20.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 25 | 25 | $14,070 | $3,511 | 25.0% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2023 | 31 | 46 | $5,550 | $1,209 | 21.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 84 | 253 | $129,972 | $27,769 | 21.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 238 | $67,354 | $19,953 | 29.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $6,982 | $1,851 | 26.5% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 37 | 56 | $6,545 | $1,610 | 24.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 15 | 16 | $2,528 | $509.60 | 20.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 54 | 456 | $129,048 | $38,569 | 29.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 80 | 262 | $129,594 | $29,551 | 22.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 18 | 18 | $9,324 | $2,673 | 28.7% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2021 | 40 | 61 | $6,887 | $1,666 | 24.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 20 | 20 | $3,076 | $629.60 | 20.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 52 | 379 | $107,257 | $31,868 | 29.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 62 | 152 | $72,713 | $13,030 | 17.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 18 | 18 | $2,664 | $587.52 | 22.1% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 14 | 19 | $2,085 | $407.17 | 19.5% |
About Dr. Ghayas Issa, M.D
Dr. Ghayas Issa, M.D is a Hematology & Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2011. The National Provider Identifier (NPI) number assigned to this provider is 1720378235.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ghayas Issa, M.D has received a total of $45,446 in payments from pharmaceutical and medical device companies, with $8,442 received in 2024. These payments were reported across 36 transactions from 9 companies. The most common payment nature is "" ($23,842).
As a Medicare-enrolled provider, Issa has provided services to 794 Medicare beneficiaries, totaling 3,014 services with total Medicare billing of $273,423. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Houston, TX
- Active Since 04/18/2011
- Last Updated 02/28/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1720378235
Products in Payments
- SCEMBLIX (Drug) $23,782
- ABL002 (Drug) $1,880
- VENCLEXTA (Drug) $550.00
- Xospata (Drug) $146.79
- DARZALEX (Biological) $64.94
- OJJAARA (Drug) $24.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Houston
Devesh Pandya, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
Elias Jabbour, M.d, M.D
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Naval Daver, Mbbs, MBBS
Hematology & Oncology — Payments: $983,097
Hematology & Oncology $983,097
Jorge Cortes-Franco, M.d, M.D
Hematology & Oncology — Payments: $927,016
Hematology & Oncology $927,016
Dr. Luis Camacho, M.d., Mph, M.D., MPH
Hematology & Oncology — Payments: $491,819
Hematology & Oncology $491,819
Christopher Flowers, M.d, M.D
Hematology & Oncology — Payments: $320,001
Hematology & Oncology $320,001